Cytokine-polymorphisms associated with Preeclampsia

A review

Carlos Mora-Palazuelos, PhD\textsuperscript{a}, Mercedes Bermúdez, PhD\textsuperscript{b}, Maribel Aguilar-Medina, PhD\textsuperscript{c}, Rosalio Ramos-Payan, PhD\textsuperscript{a}, Alfredo Ayala-Ham, PhD\textsuperscript{a}, Jose Geovanni Romero-Quintana, PhD\textsuperscript{a,}\textsuperscript{*}

Abstract

Background: Preeclampsia (PE) is a syndromic disorder that affects 2% to 8% of pregnancies and is diagnosed principally when hypertension appears in the second half of pregnancy. WHO estimates the incidence of PE to be seven times higher in developing countries than in developed countries. Severe preeclampsia/eclampsia is one of the most important causes of maternal mortality, associated with 50,000 to 100,000 annual deaths globally as well as serious fetal and neonatal morbidity and mortality, especially in developing countries. Even though evidence from family-based studies suggest PE has a heritable component, its etiology, and specific genetic contributions remain unclear. Many studies examining the genetic factors contributing to PE have been conducted, most of them are focused on single nucleotide polymorphisms (SNPs). Given that PE has a very important inflammatory component, is mandatory to examine cytokine-SNPs for elucidating all mechanisms involved in this pathology. In this review, we describe the most important cytokine-polymorphisms associated with the onset and development of PE. We aim to provide current and relevant evidence in this regard.

Methods: We searched English databases such as PubMed and the National Center for Biotechnology Information. The publication time of the papers was set from the establishment of the databases to February 2022. All studies about Th1/Th2/Th17 cytokines polymorphisms were included in our study.

Results: SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 are associated with the development, early-onset and severity of PE, being the Th1/Th2/Th17 responses affected by the presence of these SNPs.

Conclusions: The changes in Th1/Th2/Th17 response modify processes such as placentation, control of inflammation, and vascular function. Nonetheless, association studies have shown different results depending on sample size, diagnostic, and population.

Abbreviations: ACE = angiotensin I converting enzyme gene, AGT = angiotensinogen gene, AGTR1 = angiotensin II receptor type 1 gene, AGTR2 = angiotensin II receptor type 2 gene, B cells = B lymphocytes, CRP = C-reactive protein, DC = dendritic cells, DNA = deoxyribonucleic acid, F2 = coagulation factor II, F5 = coagulation factor V gene, sFlt-1 = soluble fms-like tyrosine kinase, GWAS = genome-wide association studies, HLA = human leukocyte antigen, HUVEC = human umbilical vein endothelial cell, IFN-γ = interferon-alpha, IgE = immunoglobulin E, IL-1 = interleukin 1, IL-2 = interleukin 2, IL-4 = interleukin 4, IL-6 = interleukin 6, IL-8 = interleukin 8, IL-10 = interleukin 10, IL-17 = interleukin 17, IL-17A = interleukin 17A, IL-22 = interleukin 22, ILCs = innate lymphoid cells, IUGR = intrauterine growth restriction, LTI = lymphoid tissue inducer, MALDI = matrix-assisted laser desorption/ionization, MHC = major histocompatibility complex, MHC-I = major histocompatibility complex class 1, MHC-II = major histocompatibility complex class 2, mRNA = messenger ribonucleic acid, MTHFR = methylenetetrahydrofolate reductase gene, NFAT = nuclear factor of activated T cells, NK = natural killer cells, NKT = natural killer T, NO = nitric oxide, NOS3 = nitric oxide synthase 3 gene, PCR = polymerase chain reaction, PE = Preeclampsia, PIGF = placental growth factor, PTGS2/COX-2 = cyclooxygenase-2, RFLP = restriction fragment length polymorphism, RNA = ribonucleic acid, SNP = single nucleotide polymorphism, SOCS = suppressor of cytokine signaling, TGF-β1 = transforming growth factor beta receptor 1, Th1 = T helper 1, Th2 = T helper 2, Th17 = T helper 17, Th22 = T helper 22, Th3 = T helper 3, F2 = thrombin gene, TLRs = toll-like receptors, TNF = tumor necrosis factor gene, TNF-α = tumor necrosis factor-alpha, Treg = regulatory T cells, UNG = Uracil-DNA glycosylase, VEGF = vascular endothelial growth factor, VNTR = variable number tandem repeat, WHO = World Health Organizations.

Keywords: cytokine-polymorphisms, inflammation, preeclampsia, pregnancy, SNPs
1. Introduction

Preeclampsia (PE) is a syndromic disorder that affects 2% to 8% of pregnancies and is diagnosed when hypertension appears in the second half of pregnancy. World Health Organization (WHO) estimates the incidence of PE to be seven times higher in developing countries (2.8% of live births) than in developed countries (0.4%). Severe PE/eclampsia is one of the most important causes of maternal mortality, associated with 50,000 to 100,000 annual deaths globally, as well as serious fetal and neonatal morbidity and mortality, especially in developing countries. This syndrome produces new-onset hypertension (>140/90 mm Hg) in the second half of pregnancy and is accompanied with either proteinuria (>300 mg/24 h), or multiorgan maternal dysfunction, especially kidney failure, neurological complications, thrombocytopenia, or hemolysis.

It is believed that PE results from defective spiral artery remodeling, which leads to an imbalance between anti- and pro-angiogenic factors, favoring an anti-angiogenic environment, giving as a result, widespread endothelial dysfunction and organ failure.

Serum samples have shown significantly increased soluble fms-like tyrosine kinase (sFlt-1) and decreased vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) concentrations in PE, compared to normotensive controls. In vitro studies showed that serum from PE inhibited tube formation in human umbilical vein endothelial cell (HUVEC) lines compared to that from controls, and administration of adenovirus expressing sFlt-1 to pregnant rats caused hypertension, albuminuria, and glomerular endotheliosis, similar to that observed in PE.

1.1. The genetic component of PE

The complexity of PE suggests that some women are predisposed to suffering from PE. In this regard, there is evidence supporting that PE has an outsized familial risk, with a heritability factor of approximately 50% to 55%, of which 30% to 35% is attributed to maternal genome, 20% fetal, 13% to a couple, and the rest to other effects. Family history of PE significantly increases woman’s risk of PE (24% and 163%).

Besides, it has been proved that the familial form of PE is associated with a more severe phenotype. Predisposition to PE is multifactorial and probably polygenic. Candidate genes involved in different biological processes including inflammation, coagulation, vascular resistance, cell signaling pathways, and metabolic processes have been associated with PE due to their putative roles in its pathophysiology. Most of the early candidate gene studies have been focused on just nine genes: angiotensinogen (AGT), angiotensin I converting enzyme (ACE), angiotensin II receptor type 1 (AGTR1), angiotensin II receptor type 2 (AGTR2), coagulation factor II, thrombin (F2), coagulation factor V (F5), methylenetetrahydrofolate reductase (MTHFR), nitric oxide synthase 3 (NOS3) and tumor necrosis factor (TNF), which are involved in endothelial function and hemodynamics, immune response, lipid metabolism and oxidative stress, and thrombophilia.

Attention has been also focused on increased sFlt-1 and decreased VEGF and PlGF were single nucleotide polymorphism (SNP) analyses have also shown association with PE. In this regard, genome-wide association studies (GWAS) have been performed in large cohorts of unrelated cases and controls to identify novel genetic loci through large-scale SNP analyses where the prevalence of specific SNPs is linked to phenotypes or disease. According to Brody et al., SNPs are variants in the genome occurring naturally in the human population, being the most frequent type of variation in the human genome, occurring once every several hundred base pairs throughout the genome. Each individual inherits one allele copy from each parent (the individual genotype at an SNP site is AA, BB, or AB). SNPs are defined as genomic locus where two or more alternative bases occur with appreciable frequency (0.1%). SNPs in genes can impact on messenger ribonucleic acid (mRNA) splicing, nucleo-cytoplasmic export, stability, and translation. When they are present within a coding sequence, lead to an amino acid change (referred to as a non-synonymous SNP or mutation), thus they can modify the protein’s activity. If the mutation is synonymous (does not change the nature of the amino acid), then translation rates or mRNA half-life may be affected. If the mutation causes a premature stop codon, this can lead to the production of a truncated protein product or a near-null phenotype due to nonsense mediated decay. For this, SNPs can be used as genetic markers to follow the inheritance patterns of chromosomal regions through generations and can be used in the study of genetic factors associated with human diseases.

Different technologies have been used to detect SNPs such as restriction fragment length polymorphism (RFLP), polymerase chain reaction (PCR) and genome shotgun sequencing, but they can be classically divided in technologies targeted SNP discovery (Denaturing gradient gel electrophoresis, chemical cleavage of mismatch, ribonuclease cleavage of mismatched deoxyribonucleic acid (DNA), single stranded conformation polymorphism, cleavage fragment length polymorphism analysis, MutS protein-binding assay, mismatch repair detection, T4 endonuclease VII cleavage of heteroduplex DNA, heteroduplex analysis, denaturing high performance liquid chromatography, uracil-DNA glycosylase (UNG)-mediated sequencing, ribonucleic acid (RNA) mediated finger printing with matrix-assisted laser desorption/ionization (MALDI) MS detection, sequencing by hybridization, direct DNA sequencing) and technologies for genotyping known SNPs (hybridization, primer extension, ligation, invasive cleavage, reaction formats, homogeneous reactions, reactions on solid support, detection mechanisms, luminescence detection, fluorescence detection, time- resolved fluorescence detection, fluorescence resonance energy transfer, fluorescence polarization, mass spectrometry, electrical detection).

Specifically, in PE, genetic predisposition is thought to be a significant etiological representative and SNPs in various genes were found to be associated with the risk of PE. In this regard, emerging evidence proposes that excessive maternal inflammatory response with cytokine-mediated endothelial damage may play a role in PE’s pathogenesis.

1.2. Immunology of PE

Even though the main cause of the abnormal placentation remains unclear, genetic, environmental, and immunological factors have been associated. In this regard, it is believed that both, innate and adaptive immune processes are involved in the pathogenesis of PE, proposing that Th1 immunity is responsible for poor placentaion and exacerbated inflammatory response and endothelial dysfunction seen in PE. This is relevant since T helper 1 (Th1) and T helper 2 (Th2) cytokine balance is important to maintain the success of normal pregnancy. In normal pregnancy, the production of Th1 cytokine is inhibited, and their overexpression predisposes to PE development.

Moreover, fetal trophoblast acts as an allograft producing a systemic inflammatory response in the mother, but this is controlled and mild. Inflammatory response onset during the first twelve weeks could be given by interactions occurring between the decidual immune cells and trophoblast cells, then in the second and third trimester, a secondary inflammatory response could be due to syncytiotrophoblast microparticles that are released into the mother’s vascular system and are detectable in maternal circulation.

Thus, two stages of the PE are proposed: poor trophoblastic invasion, given by altered production of immunoregulatory cytokines and angiogenic factors and a systemic, maternal-inflammatory response, primarily involving the endothelium,
which is stimulated by the liberation of necrotic/apoptotic syncytiotrophoblast cells into the maternal circulation.[17] This second stage of could be involved in poor fetal growth and can be linked with the development of intrauterine growth restriction.[16] The pathophysiology of PE may involve several factors, including persistent placental hypoxia comprised of the release of high amounts of syncytiotrophoblast microparticle. Besides, damage-associated molecular pattern molecules released during hypoxia and syncytiotrophoblast microparticle, which bind Toll-like receptors (TLRs), may activate monocytes, dendritic cells (DCs), natural killer (NK) cells, and neutrophils, enhancing persistent inflammatory conditions.[17] The development of hypertension in preeclamptic women from an immunological point of view is also related with endothelial dysfunction induced by neutrophil activation and neutrophil extravascular trap formation. Moreover, preeclamptic women have higher levels of nonclassic and intermediate monocytes and lower levels of positive lymphoid blood DC antigen 2 DCs.[39] In this regard, the inflammatory process may be due to the cytokines secreted by these cells and to changes in adaptive-immunesystem cells, which are also modulated in PE.

The changes in T cell subsets that may be seen in PE include low regulatory T cells (Treg) activity, a shift toward Th1 response, and the presence of T helper 17 (Th17) lymphocytes. B lymphocytes (B cells) can participate in the pathophysiology of PE by producing autoantibodies against adrenoreceptors and autoantibodies that bind the angiotensin-1 receptor.[40] It is believed that both, innate and adaptive immune processes are involved in the pathogenesis of PE, proposing that Th1 immunity is responsible for poor placentation and exacerbated inflammatory response and endothelial dysfunction seen in PE.[32,41] This is relevant since Th1/Th2 cytokine balance is important to maintain the success of normal pregnancy.[10,51] In normal pregnancy, the production of Th1 cytokine is inhibited, and their overexpression predisposes to PE development.[32] There are also reports showing excessive innate immune activity and a change toward an inflammatory cytokine profile in PE.[52,44] For instance, preeclamptic patients show high levels of Th1 cytokines, tumor necrosis factor-alpha (TNF-α) and interferon-gamma cytokine (IFN-γ) and low interleukin 4 (IL-4) production by phytohemagglutinin-stimulated peripheral blood mononuclear cells. Besides, their placentas show suppression of interleukin 10 (IL-10) and transforming growth factor beta receptor 1 (TGF-β receptor) and altered interleukin 2 (IL-2) IL-2/IL-10 and TNF-α/IL-10 ratios.[42] PE is also associated with increased numbers of Th17 cells that secrete interleukin 17 (IL-17) and interleukin 22 (IL-22) and play critical roles in disease development.[43] Given that IL-22 shares 22% sequence identity with IL-10, and IL-22 is overexpressed in the preeclamptic mother and neonate cord blood exposed to PE, it is thought that IL-22 may be an important inflammatory biomarker of PE.[44]

From a clinical perspective, proinflammatory cytokines, have been studied to find a panel of markers for diagnosing PE. In this regard, a systematic review showed that interleukin 6 (IL-6), interleukin 8 (IL-8), TNFα, and C-reactive protein (CRP) could be useful to identify pregnant women at risk of developing PE, particularly in the second and third trimesters.[45] Nevertheless, there is not a single inflammatory marker for routine clinical use to predict/ identify PE onset or progression.[46] Even though increased sFlt-1 and decreased VEGF and PlGF (and their SNPs) have been related with early onset of PE (Fig. 1), they are not used commonly as clinical markers. As a single cytokine is not reliable markers for early identification of PE, a combination of markers in conjunction with identification of clinical risk factors is mandatory.[46] Therefore, a broad examination of factors affecting inflammatory markers in PE could help to predict/ identify PE. Given that SNPs in genes can impact on mRNA splicing, nucleo-cytoplasmic export, stability, and translation, they must be studied. This review aims to compile the most recent information regarding SNPs in Th1, Th2 and Th17 cytokines and their association with PE.

2. Methods

A systematic search was performed on PubMed, National Center for Biotechnology Information, Web of Sciences, Google scholar, Cochrane library and Embase from 2010 to July 2022 to articles matching the following criteria: “single-nucleotide polymorphisms,” “SNP,” “polymorphisms,” “IFN-γ,” “IFN gamma,” “TNF-alpha,” “TNF-α,” “IL-4,” “IL-6,” “IL-10,” “IL-17A,” “IL-22,” and “PE,” and their combinations in lowercase letters. The Boolean operators “OR” and “AND” were used, and the strategies were carried out both individually and jointly. The titles and abstracts were screened and acquired relevant full-text manuscripts for further analysis.

No ethics committee or institutional review board needed to revise the study.

2.1. Cytokine-polymorphisms associated with PE

For a long time, single-nucleotide polymorphisms (SNPs) in cytokine have been associated with certain inflammatory diseases and obstetric complications.[47,48] Nevertheless, factors such as selection criteria, ethnic groups, and linkage disequilibrium patterns can lead to differences in results. Besides every pathophysiologic feature could have different clinical patterns. Several studies have investigated SNPs in inflammatory mediators and risk of PE; however, the results between studies showed inconsistencies (Franchim et al[49]; Ghasemi et al[50]; Andraweera et al[51]; Li et al[52]; Goddard et al[53]). This could be possible due to variations in the ethnic groups and heterogeneity of PE included in different studies. Additionally, controversial results reported by different investigators may in part be because of selection criteria. Genotype frequencies of SNPs and linkage disequilibrium patterns can differ among ethnic groups, leading to different results.[44] Moreover, distinct clinical patterns may involve different pathologic mechanisms.[51,54]

2.2. Th1 cytokines

2.2.1. IFN-γ. The interferon-gamma cytokine (IFN-γ) is encoded by the IFNG gene, also known as IFG and IFI. It is localized on chromosomal region 12q15.[55] It encodes a soluble cytokine, a member of the type II interferon class. The protein is secreted by cells of the innate and adaptive immune responses. The main functions of IFN-γ are activation of macrophages for destroying phagocytosed microorganism, stimulation, and differentiation of naive LT CD4 T into subgroup Th1 by inhibiting differentiation into Th2 phenotype, stimulation of the expression of major histocompatibility complex class 1 (MHC-I) and class 2 (MHC-II), and finally, co-stimulate antigen-presenting cells.[56,59] Moreover, IFN-γ has been associated with increased susceptibility to viral, bacterial, and parasitic infections, and it has been also related to leukemia and several autoimmune diseases.[60,61]

High levels of IFN-γ and other cytokines such as interleukin 1 (IL-1), IL-2, IL-8, and tumor necrosis factor-alpha (TNF-α) are associated with pregnancy complications such as preterm labor and intrauterine growth retardation.[52,62] In this regard, IFN-γ as well as IL-2 and TNF-α, induce trophoblastic apoptosis, restrained trophoblast differentiation that produces an incomplete trophoblastic invasion of spiral arteries, and impaired placental implantation, leading to PE.[54,63] There is only a +874A/T SNP associated with PE, in which T/T genotype in that position is related to high levels of IFN-γ production and has been associated with an increased risk of severe PE in the Brazilian population (Table 1).[48] On the other hand, the same SNP was
investigated in the Brazilian and Iranian populations, were no found association (Table 2).

2.2.2. TNF-alpha. The tumor necrosis factor-alpha cytokine (TNF-α) is encoded by the TNF gene, also known as DIF, TNFSF2, and TNLG1F. It is located in the human leukocyte antigen (HLA) class II region of the major histocompatibility complex (MHC) on chromosomal region 6p21.33.\(^\text{[84,85]}\) TNF-α is multifunctional proinflammatory Th1 cytokine, mainly secreted by macrophages, recognized for its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR.\(^\text{[85]}\) TNF-alpha is involved in the regulation of a variety of biological processes such as cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.\(^\text{[86,87]}\) Moreover, this cytokine has been implicated in a variety of diseases, including autoimmune diseases, Alzheimer, and cancer.\(^\text{[88,89]}\)

During pregnancy, TNF-α has been involved with PE etiology. In this regard, increased plasma levels of TNF-α in trophoblastic cells of the placenta have been found in preeclamptic patients while IL-10 and IL-4 levels are decreased.\(^\text{[90-92]}\) This cytokine imbalance leads to chronic peripheral and placental inflammation.\(^\text{[93]}\) In addition, there is evidence pointing to some SNPs that act as transcriptional regulators of this cytokine in the promoter region (-308G/A, -238G/A) (Table 1).\(^\text{[94]}\) Such as the G/A polymorphism at position -308 that has been associated with an increased risk of PE.\(^\text{[64,65]}\) Additionally, preeclamptic women are significantly more likely to carry the upregulating TNF-a -308 A/G than normotensive women.\(^\text{[69,82]}\) Besides, the allele frequency (AA) in -308 position is significantly higher among preeclamptic Slovak, Finnish, Iranian and the Turkish populations\(^\text{[65,67-69]}\) and eclamptic Turkish women.\(^\text{[66]}\) Interestingly, the AA allele frequency has been found significantly higher among preeclamptic patients with intrauterine growth restriction (IUGR) compared to those without IUGR in Hungary population.\(^\text{[66]}\)

Regarding G/A polymorphism at position -238, the allele G distribution is significantly higher in the PE group, moreover, is related to high levels of TNF-α production compared with the control group 136. Furthermore, the haplotype C/A, of two polymorphisms, -850C/T and -308G/A, have been associated with an increased risk of PE in the Finnish population.\(^\text{[68]}\) On the other hand, the same SNPs were investigated in the Brazilian, American, Austrian, Scottish, Italian, Finnish, and Turkish populations, where no found any association with the risk of PE (Table 2).

2.3. Th2 cytokines

2.3.1. IL-4. The interleukin 4 cytokine (IL-4) is translated by the IL4 gene, also known as BSF1; IL-4; BCGF1; BSF-1; BCGF-1 and IL4 is localized on chromosomal region 5q31.1.\(^\text{[95]}\) IL-4 protein encodes a pleiotropic cytokine Th2 produced by activated T cells. In this regard, IL-4 is considered an important cytokine for tissue repair, counteracting the effects of proinflammatory Th1 cytokines, however, it also promotes allergic airway inflammation.\(^\text{[96,97]}\) Moreover, IL-4 regulates a variety of human host responses such as allergic, anti-parasitic, wound healing, and acute inflammation.\(^\text{[98-100]}\) This protein has been reported to promote the resolution of neutrophil-mediated acute lung injury. In an allergic response, IL-4 plays a key role in the production of immunoglobulin E (Ig E).\(^\text{[101,102]}\) IL-4 cytokine is implicated in a wide variety of disease as chronic asthma, gastric cancer, breast cancer, leukemia, oral carcinoma, bladder carcinoma, colonic cancer, chronic periodontitis, and inflammatory dilated cardiomyopathy.\(^\text{[103,104]}\)

In pregnancy the Th2 cytokines, such as IL-4, play an important role in the regulation and control of inflammation, leading to the normal development of gestation. In this regard, the
## Table 1

Cytokine-SNPs associated with preeclampsia.

| Authors                  | Population studied | Population size | Methodology | SNP | Finding                                                                 |
|--------------------------|--------------------|-----------------|-------------|-----|-------------------------------------------------------------------------|
| IFN-γ                    | Pinheiro et al[48] | Brazilian SPE: 116 Ctl: 107 NP: 58 | PCR-SSP     | rs2430561 | +874T/T genotype seems to play a role in PE occurrence |
| TNF-α                    | Tavakkol Afshari et al* | Iranian PE: 153 Ctl: 54 | PCR-RFLP     | rs1800629rs361525 | Significant association between TNF-alpha G-308A and G-238A genotype and PE |
|                          | Mohajer Tehran et al[64] | Iranian PE: 160 Ctl: 100 | PCR-RFLP     | rs1800629 | Significant association between SNP of promoter region of TNF-alpha G-308A with PE |
|                          | Mirahmadian et al[65] | Iranian PE: 54 Ctl: 57 | ASO-PCR     | rs1800629rs361525 | Both, -308A and -238B allele were associated with risk of PE |
|                          | Molvarec et al[66] | Hungarian PE: 140 Ctl: 144 | PCR-RFLP     | rs1800629 | SNP G-308A was associated with risk of complicated PE with severe IUGR |
|                          | Pazarbasi et al[67] | Turkish E: 40 PE: 113 Ctl: 110 NP: 80 | PCR-RFLP     | rs1800629rs1799724 | Both SNPs were associated with the PE susceptibility |
|                          | Saarela et al[68] | Finnish PE: 133 Ctl: 130 | PCR-RFLP     | rs1799724rs1800629 | Both SNPs showed a significant haplotype association with susceptibility to PE |
|                          | Harmon et al† | American PE: 1598 Ctl: 918 | Illumina Golden- Gate Plataform | rs1800629 | Association was for PE among European Americans |
|                          | Naderi, et al‡ | Iranian PE: 100 Ctl: 100 | PCR-RFLP     | rs361525 | The AA genotype and the A allele may carry an increased risk for PE |
|                          | Puppala et al[70] | Indian PE: 100 Ctl: 100 | PCR-RFLP     | rs1800629 | SNP -308GA was associated with risk of PE |
|                          | Zubor et al[71] | Slovak PE: 38 Ctl: 38 | PCR-RFLP | rs1800629 | -308A allele was associated with risk of PE |
| IL-4                     | Fraser et al[72] | England PE: 117 Ctl: 146 | PCR-RFLP     | rs2243250 | -590T/T homozygous were associated in risk of PE |
|                          | Salimi et al[73] | Iranian PE: 192 Ctl: 186 | PCR           | rs79071878 | VNTR polymorphism of IL-4 gene has significantly increased the risk of PE |
| IL-6                     | Puppala et al[74] | Indian PE: 100 Ctl: 100 | PCR-RFLP     | rs1800795 | SNP -174G/C was associated with risk of PE |
| IL-10                    | Fan et al[75] | Chinese PE: 142 Ctl: 260 | PCR-RFLP     | rs1800872 | CC genotype of -592A/C was observed to be associated with PE |
|                          | Liu et al[76] | Chinese PE: 177 Ctl: 182 | PCR-RFLP     | rs1800872 | CC genotype of -819T/C was associated with risk of PE |
|                          | Song and Zhong[77] | Chinese PE: 177 Ctl: 182 | PCR-RFLP     | rs1800872 | -592A/C was associated with an increased risk of early-onset PE |
|                          | Sowmya et al[78] | Indian PE: 120 Ctl: 120 | ARMS-PCR     | rs1800872rs1800871 | -819C allele and -592A allele were associated with PE |
|                          | Sowmya et al§ | Indian PE: 120 Ctl: 120 | ARMS-PCR     | rs1800871 | Significant association of C allele of IL-10 -819 promoter polymorphism with PE |
|                          | Vural et al[79] | Turkish PE: 101 Ctl: 95 | ASO-PCR      | rs1800896 | AA genotype has 3.38-fold increased risk of developing PE |
|                          | Mirahmadian et al[80] | Iranian PE: 160 Ctl: 100 | ASO-PCR     | rs1800871rs1800872 | -819C and -592C alleles were associated with risk of PE |
|                          | Kamali-Sarvestani et al[81] | Iranian PE: 134 Ctl: 164 | ASO-PCR | rs1800896 | -1082G allele in PE may be considered as a genetic susceptibility to development of PE |
|                          | Daher et al[82] | Brazilian PE: 151 Ctl: 189 | PCR-SSP     | rs1800896 | SNP of IL-10 -1082 is associated with PE |
|                          | Zhou et al | Chinese PE: 117 Ctl: 286 | Multiplex PCR | rs1800896 | A-1082G allele frequency was significantly higher in PE |
|                          | Elhawary et al[83] | Egyptian PE: 20 Ctl: 20 | PCR-RFLP | rs1800896 | Significant difference between the frequency of genotype in GG, AA and A and G allele and development of PE |
|                          | Raguenma et al¶ | Tunisian PE: 345 Ctl: 300 | RT-PCR | rs1800871 | -819T/T variant and the ATA haplotype represent genetic risk for PE |
| IL-17A                   | Lang et al[84] | Chinese PE: 120 Ctl: 120 NP: 150 | PCR-RFLP | rs2275913 | Heterozygous (GA) and minor allele (A) were significantly more prevalent in PE women |
production of IL-4 is enhanced at the fetal-maternal interface during pregnancy, this production has been observed depressed in pregnant that suffering from recurring spontaneous abortio
If rats, IL-4 has proved that decrease the inflammation and ultimately, improve hypertension in response to placental ischemia.\cite{106} On the other hand, the -590C/T SNP in IL-4 has been associated with PE, in T/T genotype in that position has been associated with marked trend of PE in UK population.\cite{70} Moreover, another SNP, the variable number tandem repeat (VNTR) RP2 allele has been associated with PE susceptibility in Iranian pregnant.\cite{71}

### 2.3.2. IL-6.

The interleukin 6 cytokine (IL-6) is translated by the IL6 gene, also known as CDF; HGF; HSF; BSF-2; IL-6; BSF-2; IFNB2; IFN-beta-2 and IL-6 is localized on chromosomal region 7p15.3.\cite{107} IL-6 protein encodes a proinflammatory cytokine is primarily produced by activated cells at sites of acute and chronic inflammation. This cytokine is a soluble mediator with pleiotropic effects on inflammation and the maturation of B cells.\cite{108} Additionally, has been observed to be an endogenous pyrogen capable of inducing fever in patients with autoimmune diseases or infections.\cite{109,110} The IL-6 cytokine is implicated in a wide variety of inflammatory disease, for instance, juvenile rheumatoid arthritis, rheumatoid arthritis or susceptibility to diabetes mellitus.\cite{111,112}

There are two faces of IL-6 on Th1/Th2 differentiation.\cite{113} IL-6 promotes Th2 differentiation and at the same time inhibits Th1 polarization through two independent molecular mechanisms: IL-6 activates transcription mediated by nuclear factor of activated T cells (NFAT) leading to production of IL-6 by naïve CD4+ T cells and their differentiation into effector Th2 cells. The inhibition of Th1 differentiation by IL-6 is IL-4- and NFAT-independent. IL-6 inhibits Th1 differentiation by upregulating suppressor of cytokine signaling (SOCS)-1 expression interfering with IFN-γ signaling and the development of Th1 cells. Thus, by using two independent molecular mechanisms, IL-6 plays a dual role on Th1/Th2 differentiation.\cite{113} IL-6 is a cytokine highly expressed in the feminine tract reductive and gestational tissues and has a differential effect during pregnancy how in the development the placenta and the requirements of immunological adaptation on the fetus tolerances, in this regard IL-6 plays an important function on the pathophysiology of infertility and gestational disorders.\cite{114,115}

Preterm labor has been associated with elevated levels of maternal serum IL-6 cytokine, whereas it is observed that serum IL-6 levels increase with preeclampsic women and decreased production of IL-6 in placental tissue.\cite{116,117} In this regard, IL-6 is not essential for the success of the pregnancy, however, it is important in modulation during the implantation of the embryo.\cite{118}

Regarding SNPs, in IL-6, the -174G/C genotype has been associated with the risk of PE in the Indian population.\cite{72} But these results differ from other investigations, where a lot of groups have evaluated this SNP in Brazilian, American, Sri Lanka, Saudi, Australian, Scottish, Turkish, Finnish, Chinese and Mexican populations and they found no association with the risk of PE (Table 2).

### 2.3.3. IL-10.

The interleukin 10 cytokine (IL-10) is encoded by the IL10 gene, also known as CSIF, TGIF, GVHD5 and IL10A. It is located on the chromosomal region 1q32.1.\cite{119} The IL-10 is produced primarily by monocytes and to a lesser extent by lymphocytes. It has two principal roles, immunoregulation and inflammation. Additionally, IL-10 produces downregulation of Th1 cytokines expression, MHC class II, and co-stimulatory molecules on macrophages.\cite{120} It also helps with B cell survival, proliferation, and antibody production.\cite{110} IL-10 cytokine has been implicated in a wide variety of disease as pancreatitis, diabetic nephropathy, asthma susceptibility, ischemic stroke, and coronary artery disease.\cite{121,122}

In normal pregnancy, IL-10 has three major beneficial roles since this cytokine plays a key role in Th2 response: promoting successful placentation, controlling inflammation, and regulating vascular function.\cite{123,124} In this regard, levels of serum IL-10 are increased during a normal pregnancy and remain high until delivery. Besides, in normal human placental tissue, it has been observed higher levels of IL-10 during first and second trimesters compared to the third trimester of pregnancy, which means that provides an important balance for inflammation at the fetal-maternal interface.\cite{90,126}

Interestingly, some SNPs in the proximal (−1082A/G, −819T/C and −592A/C) and distal regions of the promoter region of the IL-10 gene\cite{127} are transcriptional regulators (Table 1).\cite{128} For instance, the A/G polymorphism at position −1082 is related to lower IL-10 production.\cite{57,129,130} It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.\cite{76,74,79}

The T/C polymorphism at position −819 found an increased distribution of the normal allele in patients\cite{71} and was associated with increased risk of PE in Chinese\cite{72} population, and with early-onset PE in an Indian population\cite{73} were specifically diplotypes of IL-10: −1082A/G with −819C and −592A/C and distal regions of the promoter region of the IL-10 gene\cite{127} are transcriptional regulators (Table 1).\cite{128} For instance, the A/G polymorphism at position −1082 is related to lower IL-10 production.\cite{57,129,130} It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.\cite{76,74,79}

The T/C polymorphism at position −819 found an increased distribution of the normal allele in patients\cite{71} and was associated with increased risk of PE in Chinese\cite{72} population, and with early-onset PE in an Indian population\cite{73} were specifically diplotypes of IL-10: −1082A/G with −819C and −592A/C and distal regions of the promoter region of the IL-10 gene\cite{127} are transcriptional regulators (Table 1).\cite{128} For instance, the A/G polymorphism at position −1082 is related to lower IL-10 production.\cite{57,129,130} It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.\cite{76,74,79}

The T/C polymorphism at position −819 found an increased distribution of the normal allele in patients\cite{71} and was associated with increased risk of PE in Chinese\cite{72} population, and with early-onset PE in an Indian population\cite{73} were specifically diplotypes of IL-10: −1082A/G with −819C and −592A/C and distal regions of the promoter region of the IL-10 gene\cite{127} are transcriptional regulators (Table 1).\cite{128} For instance, the A/G polymorphism at position −1082 is related to lower IL-10 production.\cite{57,129,130} It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.\cite{76,74,79}

The T/C polymorphism at position −819 found an increased distribution of the normal allele in patients\cite{71} and was associated with increased risk of PE in Chinese\cite{72} population, and with early-onset PE in an Indian population\cite{73} were specifically diplotypes of IL-10: −1082A/G with −819C and −592A/C and distal regions of the promoter region of the IL-10 gene\cite{127} are transcriptional regulators (Table 1).\cite{128} For instance, the A/G polymorphism at position −1082 is related to lower IL-10 production.\cite{57,129,130} It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.\cite{76,74,79}

The T/C polymorphism at position −819 found an increased distribution of the normal allele in patients\cite{71} and was associated with increased risk of PE in Chinese\cite{72} population, and with early-onset PE in an Indian population\cite{73} were specifically diplotypes of IL-10: −1082A/G with −819C and −592A/C and distal regions of the promoter region of the IL-10 gene\cite{127} are transcriptional regulators (Table 1).\cite{128} For instance, the A/G polymorphism at position −1082 is related to lower IL-10 production.\cite{57,129,130} It has been associated with an increased risk of PE in Turkish, Brazilian, and Egyptian populations.\cite{76,74,79}
### Table 2

Cytokine-SNPs not associated with preeclampsia.

| Authors                        | Population studied | Population size | Methodology         | SNP            | Finding                                                                 |
|--------------------------------|--------------------|-----------------|---------------------|----------------|-------------------------------------------------------------------------|
| **IFN-γ**                      |                    |                 |                     |                |                                                                         |
| Daher et al†                   | Brazilian PE: 151  | Ctl: 189        | PCPCR-SSP           | rs2430561      | No association in 874A/T SNP and PE was observed                         |
| Kamali-Sarvestani et al‡‡       | Iranian PE: 134    | Ctl: 164        | ASO-PCR             | rs2430561      | No association between 874A/T polymorphism and PE was observed          |
| de Lima et al‡                 | Brazilian E: 92    | Ctl: 101        | PCR-SSP             | rs2430561      | SNP of 874A/T was not association with PE women                         |
| **TNF-α**                      |                    |                 |                     |                |                                                                         |
| Daher et al†                   | Brazilian PE: 151  | Ctl: 189        | PCR-SSP             | rs1800629      | SNP of -308G/A was no associated with PE                                 |
| Pinheiro et al‡                | Brazilian SPE: 116 | Ctl: 107        | PCR-SSP             | rs1800629      | SNP of -308G/A was no associated with PE                                 |
| Livingston et al*              | American SPE: 112  | Ctl: 106        | PCR-RFLP            | rs1800629      | Neither genotypic frequency and mutant alleles were associated with severe PE SNP in G-308A was no associated with PE |
| Stonek et al¶                  | Austrian PE: 107   | Ctl: 107        | Multiplex PCR       | rs1800629      | No association between -308G/A and the risk of PE                       |
| Hagerty et al‡‡                 | American PE: 150   | Ctl: 661        | TaqMan              | rs1800629      | -308 G/A was no associated with PE                                       |
| de Lima et al‡                 | Brazilian PE: 92   | Ctl: 73         | PCR-SSP             | rs1800629      | SNP of -308G/A was no associated with PE                                 |
| Freeman et al‡                 | Scottish PE: 106   | Ctl: 212        | PCR-RFLP            | rs1800629      | No association between -308G/A and the risk of PE                       |
| Previtera and Restaino¶        | Italian SPE: 20    | Ctl: 10          | Sanger sequencing   | rs1800629      | No association was observed in -308G/A                                  |
| Heiskanen et al                 | Finnish PE: 133    | Ctl: 115        | PCR-RFLP            | rs1799724      | No association was observed in C-850T and risk of PE                     |
| Vural et al‡†                  | Turkish PE: 101    | NP: 95          | PCR-RFLP            | rs1800629      | No significant differences was found in genotype and allele frequencies in -308G/A |
| **IL-6**                       |                    |                 |                     |                |                                                                         |
| Pinheiro et al‡                | Brazilian SPE: 116 | Ctl: 107        | PCR-SSP             | rs1800795      | No association between -174G/C polymorphisms and PE was observed         |
| Andraweera et al‡              | Sri Lanka PE: 175  | Ctl: 171        | SequenomMass ARRAY system | rs1800795      | No significant differences was found in-174G/C and PE risk              |
| Freeman et al‡                 | Scottish PE: 106   | Ctl: 212        | PCR-RFLP            | rs1800795      | No association between -174G/C and the risk of PE                       |
| Vural et al‡†                  | Turkish PE: 101    | NP: 95          | PCR-RFLP            | rs1800795      | No significant differences was found in genotype and allele frequencies in -174G/C |
| Saarela et al†                 | Finnish PE: 133    | Ctl: 115        | PCR-RFLP            | rs1800795      | No significant difference was found in -17G/C and PE risk               |
| Fanet al‡‡                     | Chinese PE: 142    | Ctl: 260        | PCR-RFLP            | rs1800795rs1800796rs1800797 | No significant differences were found in genotype or allele frequencies in -174G/C, -597G/A and -572 G/C There was no association between IL-6 SNP and the risk of PE |
| Harmon et al‡                  | American PE: 1598  | Ctl: 918        | Illumina GoldenGate Platform | rs1800795      | SNP of IL-6 -174G/C was no associated with PE                           |
| Daher et al‡†                  | Brazilian PE: 91   | Ctl: 189        | PCR-SSP             | rs1800795      | No association was observed in-174G/C and risk of PE                     |
| Bayoumy et al**                | Saudi GH: 60       | PE: 49          | PCR Allele Discrimination | rs1800795      | No association was observed in-174G/C and risk of PE                     |
| Stonek et al‡†                 | Austrian PE: 14    | Ctl: 1367       | ASO-PCR             | rs1800795      | -174 G/C is not a genetic marker for risk of PE                         |
| de Lima et al‡                 | Brazilian E: 92    | Ctl: 101        | PCR-SSP             | rs1800795      | No significant difference was found in SNP of -174G/C and PE risk       |
| Valencia Villahvazo et al††    | Mexican PE: 411    | Ctl: 613        | RT-PCR              | rs1800795      | SNP of IL-6 -174G/C was no associated with PE women                     |
| Stonek et al†                  | Australian PE: 107 | Ctl: 107        | Multiplex PCR       | rs1800795      | IL-6 G174C was no associated with PE                                     |
| **IL-10**                      |                    |                 |                     |                |                                                                         |
| Kamali-Sarvestani et al‡‡       | Iranian PE: 134    | Ctl: 164        | PCR-RFLP            | rs1800871      | No association between -819T/C, -592A/C polymorphisms and PE was observed |

(Continued)
IL-17A promotes hypertension, because is traditional cardiovascular risk factor that contributes to myocardial infarction and stroke.\cite{141,143} The Th17 cells participate in pregnancy related pathologies, including recurrent spontaneous abortion and PE, and imbalances between Th1/Treg/Th17 subsets in blood circulation and uterus have been reported.\cite{83,144,147} In humans, it has been suggested that IL-17 can increase in the invasive capacity of JEG-3 cells (trophoblast-like human choriocarcinoma cell line) and increase progesterone secretion significantly.\cite{149} In normal pregnancy, the size of peripheral blood TH17 cells decrease, but in PE cases, this change is not observed, being higher in the peripheral blood and decidua.\cite{149}

Only one SNP has been reported affecting the expression of IL-17, causing recurrent pregnancy loss.\cite{149} There is an association between the heterozygous GA and the minor allele A...
functions and is involved in tissue homeostasis, tissue repair and wound healing. Although IL-22 is classified a Th17 cytokine, since is mostly coexpressed with IL-17 can be produced by a wide variety of cells from adaptive and the innate immune system: CD4+ T cells (Th1, Th17, Tc17, Tc22), CD8+ T cells (Tc17, Tc22), γδ T cells, natural killer T (NKT) cells, lymphoid tissue inducer (LTi) cells, and certain NK cell subset.

IL-22 has been related to PE. For instance, IL-22 concentration is significantly higher in PE patients group compared with the control group, resulting in the predominance of Th17- and Th22-mediated immunity in PE. This suggests that the immune imbalance among CD4+ T helper cells could lead to PE through placental ischemia. Also, Stefańska et al. showed that the IL-22, MDC, and IL2/IL-4 ratio can be used to discriminate between PE, gestation hypertension and healthy pregnancy.

As for IL-17, only one SNP has been reported affecting the expression of IL-17 (rs2227485) involved in the development of PE in the Chinese Han population. Significant differences were found between PE patients and controls for this SNP in terms of genotypic frequencies (P < .001). Then rs2227485 was assessed under the dominant model of the C allele (CC/CT + TT genotype) or the recessive model of the T allele (TT/CC + CT genotype), and observed a significant difference under the recessive model of the T allele (P < .001, OR = 0.620, 95% CI 0.495–0.776).

3. Discussions
Pathophysiology of PE is multifactorial, being the abnormal placentation a key factor that can trigger endothelial system dysfunction and dysregulation of the inflammatory process. Nevertheless, genetic aspects also play a very important role in the development of PE. PE is a complex and multi-symptomatic disease in which onset time, severity, and development can be a reflex of multiple genotypes. In this regard, considering that cytokines are involved in PE pathogenesis and that cytokine gene polymorphism may affect cytokine production it is obvious to seek for association between these candidate SNPs and PE.

Until now, SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 have shown a clear association with the development, early-onset and severity of PE. In this regard, Th1, Th2, and Th17 responses are modified by the presence of these SNPs, affecting processes such as placentation, control of inflammation, and vascular function (Fig. 2). Nevertheless, association studies have shown different results depending on sample size, diagnostic, and population. More extensive studies could help to have more accurate conclusions about how cytokine genotypes should be considered in clinical practice since PE remains a very serious public health problem.

4. Conclusions
SNPs in IFN-γ, TNF-α, IL-4, IL-6, IL-10, IL-17A, and IL-22 have a clear association with the development, early-onset and severity of PE, modifying the Th1, Th2, and Th17 responses, affecting processes such as placentation, control of inflammation, and vascular function. Nevertheless, association studies...
have shown different results depending on sample size, diagnosis, and population.

Author contributions

Conceptualization: Carlos Mora-Palazuelos, Mercedes Bermúdez, Maribel Aguilar-Medina.

Data curation: Carlos Mora-Palazuelos, Mercedes Bermúdez, Maribel Aguilar-Medina, Alfredo Ayala-Ham.

Methodology: Carlos Mora-Palazuelos, Maribel Aguilar-Medina, Alfredo Ayala-Ham.

Writing – original draft: Carlos Mora-Palazuelos, Mercedes Bermúdez, Maribel Aguilar-Medina, Rosalio Ramos-Payan, Jose Geovanni Romero-Quintana.

Writing – review & editing: Rosalio Ramos-Payan, Jose Geovanni Romero-Quintana.

References

[1] Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135:e237–60.

[2] WHO. Make Every Mother and Child Count, in the World Health Report 2005. Geneva, Switzerland: World Health Organization; 2005.

[3] Oyston CJ, Stanley JL, Baker PN. Potential targets for the treatment of preeclampsia. Expert Opin Ther Targets. 2015;19:1517–30.

[4] ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol. 2019;133:e1–25.

[5] Burton GJ, Redman CW, Roberts JM, et al. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 2014;168:335–45.

[6] Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: revisiting concepts, physiopathology, and prediction. Sci World J. 2018;2018:19.

[7] Kenny LC, Black MA, Poston L, et al. Early pregnancy prediction of preeclampsia identifies maternal association at PLEKH1. Hypertension. 2018;72:408–16.

[8] Darmochwal-Kolarz D, Rolinski J, Tabarkiewicz J, et al. Myeloid and proteolytic pathways in the pathogenesis of preeclampsia. J Perinat Med. 2003;31:323–44.

[9] Sivaraj N, Rachel KV, Suvvari TK, et al. Association of IL1R1 gene A874T polymorphism and risk of preterm birth: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2011;158:61–5.

[10] Kwok PY, Chen X. Detection of single nucleotide polymorphisms. Curr Opin Genet Dev. 2000;10:330–4.

[11] Wang Z, Liu M, Song H, et al. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage. Reprod Biol Endocrinol. 2017;15:95.

[12] Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract. 2013;22(suppl 1):8–19.

[13] Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61:932–42.

[14] Liu M, Zhen X, Song H, et al. Genes and the pre-eclampsia syndrome. Mol Aspects Med. 2007;28:192–209.

[15] Szarka A, Rigó J Jr, Lázár L, et al. The role of the immune system in the pathophysiology of preeclampsia. Cold Spring Harb Perspect Med. 2015;5:a023473.

[16] Dong M, He J, Wang Z, et al. Placental imbalance of Th1- and Th2-type cytokines in preeclampsia, but not normotensive intrauterine growth restriction. Placenta. 2008;27:56–61.

[17] Darmochwal-Kolarz D, Rolinski J, Tabarkiewicz J, et al. Interleukin-22: biomarker of maternal association at PLEKH1. J Perinat Med. 2003;31:323–44.

[18] Szarka A, Rigó J Jr, Lázár L, et al. The role of the immune system in the pathophysiology of preeclampsia. J Coll Physicians Surg Pak. 2015;25:677–80.

[19] Liu M, Zhen X, Song H, et al. Potential targets for the treatment of preeclampsia. Expert Opin Ther Targets. 2015;19:1517–30.

[20] Burton GJ, Redman CW, Roberts JM, et al. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 2014;168:335–45.

[21] Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: revisiting concepts, physiopathology, and prediction. Sci World J. 2018;2018:19.

[22] Sivaraj N, Rachel KV, Suvvari TK, et al. Association of IL1R1 gene A874T polymorphism and risk of preterm birth: a meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2011;158:61–5.

[23] Kwok PY, Chen X. Detection of single nucleotide polymorphisms. Curr Opin Genet Dev. 2000;10:330–4.

[24] Wang Z, Liu M, Song H, et al. Low-dose lymphocyte immunotherapy rebalances the peripheral blood Th1/Th2/Treg paradigm in patients with unexplained recurrent miscarriage. Reprod Biol Endocrinol. 2017;15:95.

[25] Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract. 2013;22(suppl 1):8–19.

[26] Staff AC, Benton SJ, von Dadelszen P, et al. Redefining preeclampsia using placenta-derived biomarkers. Hypertension. 2013;61:932–42.

[27] Liu M, Zhen X, Song H, et al. Genes and the pre-eclampsia syndrome. Mol Aspects Med. 2007;28:192–209.

[28] Szarka A, Rigó J Jr, Lázár L, et al. The role of the immune system in the pathophysiology of preeclampsia. Cold Spring Harb Perspect Med. 2015;5:a023473.

[29] Dong M, He J, Wang Z, et al. Placental imbalance of Th1- and Th2-type cytokines in preeclampsia, but not normotensive intrauterine growth restriction. Placenta. 2008;27:56–61.

[30] Darmochwal-Kolarz D, Rolinski J, Tabarkiewicz J, et al. Interleukin-22: biomarker of maternal association at PLEKH1. J Perinat Med. 2003;31:323–44.

[31] Szarka A, Rigó J Jr, Lázár L, et al. The role of the immune system in the pathophysiology of preeclampsia. J Coll Physicians Surg Pak. 2015;25:677–80.

[32] Liu M, Zhen X, Song H, et al. Potential targets for the treatment of preeclampsia. Expert Opin Ther Targets. 2015;19:1517–30.
[50] Ghasemi M, Kashani E, Fayyaz A, et al. Interleukin-1 alpha variation is associated with the risk of developing preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2015;193:75–8.

[51] Andraweera P, Dyke RR, Jayasrika RW, et al. Polymorphisms in the inflammatory pathway genes and the risk of preeclampsia in Sinhalese women. J Matern-Fetal Neonatal Med. 2016;29:1072–6.

[52] Li J, Liu M, Zong J, et al. Genetic variations in IL1A and IL1RN are associated with the risk of preeclampsia in Chinese Han population. Sci Rep. 2014;4:5230.

[53] Goddard KA, Blangy D, Romero R, et al. Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered. 2007;63:1–16.

[54] Hassan MI, Aschner Y, Manning CH, et al. Racial differences in selected cytokine allelic and genotypic frequencies among healthy, pregnant women in North Carolina. Cytokine. 2003;21:10–6.

[55] Hirschmugl C, Oreshki A, Matsushita S, et al. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. Hypertens Res. 2008;31:1541–1548.

[56] de Lima THB, Sass N, Mattar R, et al. Cytokine gene polymorphisms in preeclampsia and eclampsia. Hypertens Res. 2009;32:563–569.

[57] NIH. IFNG gene. 04/12/2018. Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/IFNG#location [access date January 31, 2020].

[58] Bao Y, Liu X, Han C, et al. Identification of IFN-α-producing innate B cells. Cell Res. 2014;24:161–76.

[59] Ferreira VL, Borba HHL, Bonetti AdF, et al. Cytokines and interferons: types and functions. In: Cytokines A, Khan WA, eds. IntechOpen. London, UK: 2018.

[60] NCBI. IFNG interferon gamma [Homo sapiens (human)]. Available at: https://www.ncbi.nlm.nih.gov/gene/3458 [access date April 20, 2020].

[61] Wei Z, Wenhao S, Yuanyuan M, et al. A single nucleotide polymorphism in the interferon-γ gene (IFNG +874 T/A) is associated with susceptibility to tuberculosis. Oncotarget. 2017;8:30415–29.

[62] Sykes L, MacIntyre DA, Yap XJ, et al. The Th1/Th2 dichotomy of pregnancy and preterm labour. Mediators Inflamm. 2012;2012:967629.

[63] Serrano NC. Immunology and genetic of preeclampsia. J Immunol. 2006;173(4):197–201.

[64] Mohajerstefan F, Tavakkol Afshari J, Rezaeeyazdi Z, et al. Association of single nucleotide polymorphisms in the human tumor necrosis factor alpha and interleukin 1-beta genes in patients with preeclampsia. Iran J Allergy Asthma Immunol. 2012;11:224–9.

[65] Mirahmadian M, Kalantar F, Heidari G, et al. Association of tumor necrosis factor-α polymorphisms and risk of Chinese Han women. J Cell Biochem. 2018;119:4656–63.

[66] Haggerty CL, Ferrell RE, Hubel CA, et al. Association between allelic variants in cytokine genes and preeclampsia. Am J Obstet Gynecol. 2005;193:209–15.

[67] Anvari F, Dabaghi-Gorjani F, Soltani-Zangbar MS, et al. Investigating the association of IL-1A and IL-1F with susceptibility to pre-eclampsia in Iranian women. Iran J Immunol. 2015;12:117–28.

[68] Kilpatrick DC. Influence of human leukocyte antigen and tumour necrosis factor genes on the development of pre-eclampsia. Hum Reprod Update. 1999;5:94–102.

[69] NCBI. TNF Tumor Necrosis Factor [Homo Sapiens (human)]. Available at: https://www.ncbi.nlm.nih.gov/gene/7124.

[70] Cibler M, Whalen CA, Zglavcova M, et al. The role of tumor necrosis factor α in the biology of uterine fibroids and the symptoms. Int J Mol Sci. 2018;19:3869.

[71] Bradley JR. TNF-mediated inflammatory disease. J Pathol. 2008;214:149–60.

[72] Gupta M, Babic A, Beck AH, et al. TNF-alpha expression, risk factors, and inflammatory exposures in ovarian cancer: evidence for an inflammatory pathway of ovarian carcinogenesis? Hum Pathol. 2016;54:82–91.

[73] Decourt B, Lahiri DK, Sabbagh MN. Targeting tumor necrosis factor alpha for Alzheimer’s disease. Curr Alzheimer Res. 2017;14:412–25.

[74] Harmon AC, Cornelius DC, Amaral LM, et al. The role of inflammation in the pathology of preeclampsia. Clin Sci (Lond). 2016;130:409–19.

[75] Emerson J, Berg C, Mjosberg J. Regulatory T helper cells in pregnancy and their roles in systemic versus local immune tolerance. Am J Reprod Immunol. 2011;66(1):31–43.

[76] Hennessy A, Plimhol HL, Simmons LA, et al. A deficiency of placent al IL-10 in preeclampsia. J Immunol. 1999;163:3491–5.

[77] Campos-Canas J, Romo-Palafoux I, Albani-Campanario M, et al. An imbalance in the production of proinflammatory and anti-inflammatory cytokines is observed in whole blood cultures of preeclamptic women in comparison with healthy pregnant women. Hypertens Pregnancy. 2014;33:236–49.

[78] Abraham LJ, Kroeger KM. Impact of the -308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol. 1999;66:562–6.

[79] NCBI. IL4 interleukin 4 [Homo sapiens (human)]. Available at: https://www.ncbi.nlm.nih.gov/gene/5365.

[80] Foster PS, Maltby S, Rosenberg HF, et al. Modeling T(H) 2 responses and airway inflammation to understand fundamental mechanisms regulating the pathogenesis of asthma. Immunol Rev. 2017;278:20–40.

[81] Kirstein F, Nieuwenhuizen NE, Jayakumar J, et al. Role of IL-4 receptor α-positive CD4+ T cells in chronic airway hyperresponsiveness. J Allergy Clin Immunol. 2016;137:1852–62.e9.

[82] Hershey GKK, Friedrich ME, Esswein LA, et al. The association of Atopy with a gain-of-function mutation in the α subunit of the interleukin-4 receptor. 1997;337:1720–25.

[83] Schmidt-Weber CB. Anti-IL-4 as a new strategy in allergy. Chem Immunol Allergy. 2012;96:120–5.

[84] Dayakar A, Chandrasekaran S, Kuchipudi SV, et al. Cytokines: key determinants of resistance or disease progression in visceral leishmaniasis: opportunities for novel diagnostics and immunotherapy. Front Immunol. 2019;10:670.

[85] Robinson MJ, Przybylo M, Mears H, et al. IL-4 haplinsufficiency specifically impairs IgE responses against allergens in mice. J Immunol. 2017;198:1815–22.

[86] Savelkoul HF, van Ommen R. Role of IL-4 in persistent IgE formation. Eur Respir J. 1996;22:676–71s.
[103] Liu H, Antony S, Roy K, et al. Interleukin-4 and interleukin-13 increase NADPH oxidase 1-related proliferation of human colon cancer cells. Oncotarget. 2017;8(38):61335–45.

[104] Davtyan NL, Bala MC, Harnau MV, et al. Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy. J Exp Med. 2017;214:943–57.

[105] Piccinni MP, Beloni L, Livi C, et al. Defective production of both leukaemia inhibitory factor and type 2 Th-helper cytokines by dendritic cells in unexplained recurrent abortions. Nat Med. 1998;4:1020–4.

[106] Gottrell NJ, Amaro LC, Harmion AM, et al. Interleukin-4 supplementation improves the pathophysiology of hypertension in response to placentation in RUPP rats. Am J Physiol Regul Integr Comp Physiol. 2019;316:R165–71.

[107] NCBI. IL6 interleukin 6 [Homo sapiens (human)]. 2020. Available at: https://www.ncbi.nlm.nih.gov/gene/3605.

[108] Lübbert E. The IL-23–IL-17 axis in inflammatory arthritis. Nat Rheumatol. 2015;11:415–29.

[109] Cui D, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol. 2010;10:479–89.

[110] Fu S, Jin J, Purohit K, et al. Interleukin-17A and keratinocytes in psoriasis. Int J Mol Sci. 2020;21:1275.

[111] von Stebut E, Boehncke WH, Goreschi K, et al. IL-17A in pso- asis and beyond: cardiovascular and metabolic implications. Front Immunol. 2020;10:3096.

[112] Amatya N, Garg AV, Gaffan SL. IL-17 signaling: the Yin and the Yang. Trends Immunol. 2017;38:310–22.

[113] Kawai Tokuha, Ishioka, M., et al. The role of IL-17 and related cytokines in inflammatory autoimmune diseases. 2017:3908061.

[114] Kuestner RE, Taft DW, Haran A, et al. Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007;179:5462–73.

[115] Robert M, Miossec P. Effects of Interleukin 17 on the cardiovascular system. Autoimmun Rev. 2017;16:984–91.

[116] Sun J, Zhang S, Zhang X, et al. IL-17A is implicated in lipopolysaccharide-induced neuroinflammation and cognitive impairment in aged rats via microglial activation. J Neuroinflammation. 2015;12:165.

[117] Li, Wang L, Wang S, et al. The Treg/Th17 imbalance in patients with idiopathic dilated cardiomyopathy. Scand J Immunol. 2010;71:298–303.

[118] Sato S, Nakashima A, Ito M, et al. Clinical implication of recent advances in our understanding of IL-17 and reproductive immunology. Expert Rev Clin Immunol. 2011;7:649–57.

[119] Sato S, Nakashima A, Shima T, et al. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol. 2010;63:601–10.

[120] Cornelius DG, Lamarca B. TH17- and IL-17- mediated autoantibodies and placental oxidative stress play a role in the pathophysiology of pre-eclampsia. Minerva Ginecol. 2014;66:243–9.

[121] Shields CA, McCalmon M, Ibrahim T, et al. Placental placental immune-stimulated T-helper cells induce preeclampsia-associated cytolytic natural killer cells during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2018;315:R336–43.

[122] Pongcharoen S, Supalap K. Interleukin-17 increased progesterone secretion by JEG-3 human choriocarcinoma cells. Am J Reprod Immunol. 2009;61:261–4.

[123] Fu B, Tian Z, Wei H. TH17 cells in human recurrent pregnancy loss and pre-eclampsia. Cell Mol Immunol. 2014;11:564–70.

[124] Najafi S, Hadimdehoushan H, Eslami G, et al. Association of IL-17A and IL-17 F gene polymorphisms with recurrent pregnancy loss in Iranian women. J Assist Reprod Genet. 2014;31:1491–6.

[125] Rutz S, Eldschun C, Ouyang W. IL-22, not simply a Th17 cytokine. Trends Immunol. 2017;38:310–22.

[126] Stefa M, Jankowiak M, et al. Cytokine imprint in idiopathic dilated cardiomyopathy. Scand J Immunol. 2010;71:1885–95.

[127] Watson CJ, Webb NJ, Bottomley MJ, et al. Identification of polymorphisms in the development of acute pancreatitis. Genet Mol Res. 2016;15:gmr.15027743.

[128] Shields CA, McCalmon M, Ibrahim T, et al. Placental placental immune-stimulated T-helper cells induce preeclampsia-associated cytolytic natural killer cells during pregnancy. Am J Physiol Regul Integr Comp Physiol. 2018;315:R336–43.

[129] Pongcharoen S, Supalap K. Interleukin-17 increased progesterone secretion by JEG-3 human choriocarcinoma cells. Am J Reprod Immunol. 2009;61:261–4.

[130] Fu B, Tian Z, Wei H. TH17 cells in human recurrent pregnancy loss and pre-eclampsia. Cell Mol Immunol. 2014;11:564–70.

[131] Najafi S, Hadimdehoushan H, Eslami G, et al. Association of IL-17A and IL-17 F gene polymorphisms with recurrent pregnancy loss in Iranian women. J Assist Reprod Genet. 2014;31:1491–6.

[132] Rutz S, Eldschun C, Ouyang W. IL-22, not simply a Th17 cytokine. Trends Immunol. 2017;38:310–22.

[133] Stefa M, Jankowiak M, et al. Cytokine imprint in idiopathic dilated cardiomyopathy. Scand J Immunol. 2010;71:1885–95.
[159] Srinivas SK, Morrison AC, Andrela CM, et al. Allelic variations in angiogenic pathway genes are associated with preeclampsia. Am J Obstet Gynecol. 2010;202:445.e1–11.

[160] Amosco MD, Villar VA, Naniong JM, et al. VEGF-A and VEGFR1 SNPs associate with preeclampsia in a Philippine population. Clin Exp Hypertens. 2016;38:578–85.

[161] Shim JY, Jun JK, Jung BK, et al. Vascular endothelial growth factor gene +936 C/T polymorphism is associated with preeclampsia in Korean women. Am J Obstet Gynecol. 2007;197:271.e1–4.

[162] Papazoglou D, Galazios G, Koukourakis MI, et al. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod. 2004;10:321–4.

[163] Hamid HM, Abdalla SE, Sdigi M, Adam I. Association of VEGFA and IL1β gene polymorphisms with preeclampsia in Sudanese women. 2020;8:e1119.

[164] Niktalab R, Piravar Z, Behzadi R. Different polymorphisms of vascular endothelial growth factor gene in patients with Pre-Eclampsia among The Iranian Women Population. Int J Fertil Steril. 2020;14:41–5.

[165] Salimi S, Yaghmaei M, Tabatabaei E, et al. Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level. J Obstet Gynaecol Res. 2013;41:1877–83.

[166] Duan W, Xia C, Wang K, et al. A meta-analysis of the vascular endothelial growth factor polymorphisms associated with the risk of pre-eclampsia. Biosci Rep. 2020;40:BSR20190209.

[167] Andraweera PH, Dekker GA, Dissanayake VHW, et al. Vascular endothelial growth factor family gene polymorphisms in preeclampsia in Sinhalese women in Sri-Lanka. J Matern Fetal Neonatal Med. 2013;26:532–6.